Evidence map›Paper›PMID 38098217›Full record

ReviewCancer medicine2023

The role of tumor-associated macrophages in hepatocellular carcinoma progression: A narrative review.

Xinyi Zhang, Chao Yu, Siqi Zhao, Min Wang, Longcheng Shang, Jin Zhou, Yong Ma

Open access · goldAbstract readReview
In one paragraph

Review in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xinyi ZhangDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID 0000-0001-5421-7385
Chao YuDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Siqi ZhaoDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Min WangDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Longcheng ShangDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jin ZhouDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yong MaDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CN

Funding

Chen Xiaoping foundation for the development of science and technology of Hubei Province CXPJJH12000009-08National Natural Science Foundation of China 82203762Xinghuo Talent Program of Nanjing First Hospital
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world, with complex etiology and mechanism, and a high mortality rate. Tumor-associated macrophages (TAMs) are an important part of the HCC tumor microenvironment. Studies in recent years have shown that TAMs are involved in multiple stages of HCC and are related to treatment and prognosis in HCC. The specific mechanisms between TAMs and HCC are gradually being revealed. This paper reviews recent advances in the mechanisms associated with TAMs in HCC, concentrating on an overview of effects of TAMs on drug resistance in HCC and the signaling pathways linked with HCC, providing clues for the treatment and prognosis determination of HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansMacrophagesSignal TransductionTumor-Associated MacrophagesTumor Microenvironmentdrug resistancehepatocellular carcinomasignaling pathwaytumor-associated macrophagestumor microenvironment

Identifiers

PMID38098217
PMCPMC10757104
OpenAlexW4389792096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.